053 – Amarin Raises Guidance on Vascepa Label Expansion. ASH Updates Impress!

Amarin finally receives label expansion for Vascepa, which can now be marketed to patients with Triglyceride levels of greater or equal to 150mg/dl and existing Cardiovascular Disease or Diabetes Mellitus plus two other risk factors for CVD. In this video, I go through what I think is the potential market for this drug and the company’s valuation. I also talk about a number of other companies that had updates at ASH2019 or around that time, including BLUE, FATE, DTIL, KOD, SRPT, SNY.

Follow me on twitter @matthewlepoire

Email me at matthewlepoire@gmail.com

Relevant sources:

  • Fan W. Diabetes. 2018:67(Suppl 1)
  • 2019 AHA Heart Disease and Stroke Statistics
  • Fan W. J Clin Lipidol. 2018:13(1)
  • Einarson TR. Cardio Diabetol. 2018 17(83)

Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.

 

046 – FDA Announces Last Minute Advisory Committee For Amarin’s Vascepa

Hey everyone! In this video, I discuss the relationship history between Amarin and the FDA regarding their EPA medication (Vascepa) for the lowering of triglycerides. I believe the difficulty #AMRN has had with the FDA in the past has made the market concerned about Vascepa’s future given recent announcement of an advisory committee meeting for label expansion of Vascepa. I also talk about Sarepta, Novartis and Gilead. Thanks for watching!

For my previous analysis of Amarin, check out #034.

*This is not investment advice. Please do your own due diligence before ever investing in equity markets.*

http://www.breakingbiotech.com
Great resource on Amarin’s approval issues with the FDA

 

034 – FDA’s Gottlieb Resigns plus AMRN Breakdown

In this episode, I talk about the latest news in the biotech sector with details on my DCF model for Amarin and their fish oil pill, vascepa. I also talk about the limb-girdle data from Sarepta.

Hit the like and subscribe button!

*this is not investment advice*

http://www.breakingbiotech.com

 

027 – Amarin Sells Off Amid Positive Vascepa Data

Amarin recently published data from their REDUCE-IT cardiovascular outcomes trial. Their EPA medicine, Vascepa, showed a 25% relative risk reduction compared to placebo. EPA is an omega-3 fatty acid that previously showed a 19% relative risk reduction in cardiovascular outcomes in a Japanese study (JELIS, 2007). Amarin saw a hazard ratio of 0.75 in their primary endpoint, which evaluated cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. In this video, I go through two critiques of the study:
1) Lack of mechanistic insight
2) Mineral oil use in the placebo group
I believe Vascepa is likely to get FDA approval for the indication of reducing cardiovascular disease in patients with over 150mg/dl Triglycerides on statin therapy.

This is not investment advice, do your own due diligence.

Relevant links:
https://investor.amarincorp.com/
https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
https://www.nejm.org/doi/full/10.1056/NEJMe1814004

 
%d bloggers like this: